Carcinoma in situ of unspecified part of intestine
ICD-10 D01.40 is a billable code used to indicate a diagnosis of carcinoma in situ of unspecified part of intestine.
Carcinoma in situ (CIS) of the intestine refers to a localized cancer that has not invaded surrounding tissues. This condition is characterized by abnormal cells that are confined to the epithelial layer of the intestinal lining. The term 'unspecified part of intestine' indicates that the precise location within the intestinal tract—whether it be the small intestine, large intestine, or rectum—is not clearly defined. CIS is considered an early stage of cancer, and while it is not life-threatening at this stage, it has the potential to progress to invasive cancer if left untreated. Surveillance protocols typically involve regular monitoring through colonoscopy or imaging studies to detect any changes in the cellular structure or the emergence of invasive cancer. The risk of progression varies based on factors such as the histological type of the carcinoma, patient age, and underlying health conditions. Early detection and intervention are crucial for improving patient outcomes and preventing the transition to invasive disease.
Detailed pathology reports, treatment plans, and follow-up notes.
Diagnosis of carcinoma in situ during routine screenings, management of patients with a history of intestinal polyps.
Ensure clear documentation of the carcinoma's characteristics and any treatment interventions.
Endoscopy reports, biopsy results, and surveillance protocols.
Routine colonoscopy revealing carcinoma in situ, monitoring patients post-polypectomy.
Accurate coding of the procedure and findings is essential for proper billing.
Used during routine screenings or follow-ups for patients with carcinoma in situ.
Endoscopy report detailing findings and any biopsies taken.
Gastroenterologists should ensure accurate coding of findings.
Carcinoma in situ is an early form of cancer that has not spread beyond its original site. It is crucial for early detection and intervention to prevent progression to invasive cancer.
